Assessment of the Safety and Efficacy Data for the Hypnotic Halcion(R): Results of an Analysis by an Institute of Medicine Committee
| Autor: | Keith F. Killam, Daniel L. Azarnoff, David J. Kupfer, John H. Krystal, William E. Bunney, Sandra Hullett, Andrew M. Pope, Robert Cancro, Robert D. Gibbons, Geoffrey S. French, Byron W. Brown, Gillin Jc, Paul D. Stolley |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Statistics and Probability
medicine.medical_specialty Triazolam business.industry medicine.drug_class Amnesia Hypnotic Sedative medicine Insomnia Anxiety Statistics Probability and Uncertainty medicine.symptom Medical prescription business Psychiatry Depression (differential diagnoses) medicine.drug |
| Zdroj: | Journal of the American Statistical Association. 94:993-1002 |
| ISSN: | 1537-274X 0162-1459 |
| Popis: | Recent estimates indicate a 10% prevalence of chronic insomnia in the adult population of the United States, with an associated annual cost of more than $90 billion. Since its approval in 1982 for use in the treatment of insomnia, an estimated 11 billion prescriptions for Halcion(R) (triazolam) have been filled worldwide. Concerns about the safety of Halcion began to emerge when a Dutch psychiatrist reported a possible link between the drug and a syndrome that included depression, amnesia, hallucinations, and anxiety. Since that time, the United Kingdom, Brazil, Argentina, Norway, and Denmark removed Halcion from the market, and the manufacturer, Upjohn, withdrew Halcion from the market in The Netherlands. Other countries, including the United States and Canada, modified the labeling to reduce the recommended dose and duration of treatment and to heighten awareness regarding possible side effects affecting behavior and cognition. The labeling changes raised questions regarding the hypnotic effect... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|